The Macerich (MAC) news
Recent news
Novo says Ozempic 2 mg associated with lower cardio events risk
New real-world data from the SCORE study, presented at the American College of Cardiology Annual Scientific Session and Expo (ACC.25), indicates that semaglutide 2.4 mg is associated with 57% reduction in MACE among patients with obesity or overweight and established cardiovascular disease. The…
AInvest Wire · Sep 29, 2026Macerich raised to outperform vs in line at Evercore
Evercore ISI Group has raised its rating for Macerich (MAC) to "Outperform" from "In-Line," according to recent analyst activity. The upgrade was accompanied by an increase in the price target to $20.00 from $18.00, representing an 11.11% adjustment . This move reflects a more optimistic outlook…
AInvest Wire · Sep 21, 2026The Macerich Company - Partnership prices $675 mln 2.25% exchangeable senior notes due 2031
AInvest Wire · Aug 7, 2026Macerich is said to offer 20%-25% conversion premium on bond
Macerich (NYSE: MAC) has recently been noted for offering a 20%-25% conversion premium on its convertible bonds, a feature that may appeal to investors seeking a balance between equity upside and fixed-income stability. While the company has not disclosed specific details about its convertible bond…
AInvest Wire · Aug 6, 2026Macerich is said to offer 2%-2.5% coupon on exchangeable bond
AInvest Wire · Aug 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.